Company Dynamics - Guangzhou Xiangxue Pharmaceutical Co., Ltd. (ST Xiangxue) is facing multiple challenges, with over 92.26 million yuan in litigation amounts disclosed in the past year, accounting for 8.78% of the company's latest audited net assets [2] - The company has been involved in significant legal disputes, including a contract dispute amounting to 20.92 million yuan and a financial loan dispute totaling 44.96 million yuan [2] - Established in 1986, ST Xiangxue has developed a full industry chain from traditional Chinese medicine cultivation to production and distribution, with core products including medicinal syrups and granules [2] Financial Performance - Since 2016, ST Xiangxue's net profit has declined significantly, with a drop of over 60% in 2016 to 66.02 million yuan, and subsequent years maintaining net profits between 60 million and 70 million yuan [3] - The company reported a loss of 677 million yuan in 2021, followed by losses of 530 million yuan, 389 million yuan, and 859 million yuan in 2022, 2023, and 2024 respectively [3] - In January 2025, the company received a notice from creditor Guangdong Jinglong Construction Group, leading to a pre-restructuring application due to its inability to repay debts [3] Restructuring Efforts - The pre-restructuring process was approved by the Guangzhou Intermediate People's Court, initially set for three months but has faced multiple extensions, now extended to January 11, 2026 [3][4] - Despite ongoing restructuring efforts, the company projected a significant loss for 2025, estimating a net loss between 635 million yuan and 934 million yuan [4] - Contributing factors to the losses include intensified market competition, liquidity issues, high financial costs, and asset impairment provisions totaling approximately 130 million yuan [4][5]

Company Dynamics - Guangzhou Xiangxue Pharmaceutical Co., Ltd. (stock code: ST Xiangxue, 300147.SZ) is currently facing multiple challenges, with litigation amounts exceeding 92.26 million yuan in the past year, accounting for 8.78% of its latest audited net assets [2] - Major lawsuits include a contract dispute with Guangzhou Wanbo Jiacheng Venture Capital Co., Ltd. involving 20.92 million yuan and a financial loan dispute with a bank amounting to 44.96 million yuan [2] - The impact of these lawsuits on the company's current and future profits remains uncertain as some cases are still under trial or unresolved [2] Financial Performance - Since 2016, the company's performance has been declining, with net profit dropping over 60% to 66.02 million yuan in that year [3] - The net profit has remained between 60 million and 70 million yuan in subsequent years, but a significant loss of 677 million yuan was recorded in 2021 [3] - Continuous losses are projected for 2022 to 2024, with losses of 530 million yuan, 389 million yuan, and 859 million yuan respectively [3] - In early 2025, the company initiated a pre-restructuring process due to its inability to fulfill legal obligations and a lack of debt repayment capacity [3] Restructuring Process - The Guangzhou Intermediate People's Court approved the company's pre-restructuring, initially set for three months, but it has faced two delays, extending the deadline to January 11, 2026 [3] - The pre-restructuring is a preliminary step before formal restructuring, and there is uncertainty regarding whether the company will enter the restructuring process [3] 2025 Financial Forecast - The company forecasts a net loss of between 635 million yuan and 934 million yuan for the entire year of 2025, with a non-recurring net profit loss estimated between 612 million yuan and 899 million yuan [4] - Contributing factors to this loss include intensified market competition, liquidity crisis leading to reduced revenue and gross margin, high financial costs, asset depreciation, impairment provisions, and extraordinary expenses [4] - Specific financial burdens include significant short-term and long-term borrowings with financial costs around 250 million yuan, fixed asset depreciation and amortization affecting approximately 200 million yuan, and expected asset impairments totaling about 130 million yuan [4]

Core Viewpoint - ST Xiangxue Pharmaceutical Co., Ltd. is facing multiple challenges, including significant legal disputes and ongoing financial losses, which have led to a pre-restructuring process initiated in early 2025 [1][3][4]. Group 1: Legal Issues - The company and its subsidiaries have been involved in lawsuits totaling approximately 92.27 million yuan over the past year, which accounts for 8.78% of the latest audited net assets [1]. - Major legal disputes include a contract dispute with Guangzhou Wanbo Jiacheng Venture Capital involving 20.92 million yuan and a financial loan dispute with Agricultural Bank of China involving 44.96 million yuan [1]. Group 2: Financial Performance - ST Xiangxue has experienced a decline in net profit since 2016, with a significant loss of 677 million yuan in 2021, followed by continued losses of 530 million yuan in 2022, 389 million yuan in 2023, and an expected loss of 859 million yuan in 2024 [2]. - The company anticipates a net profit loss of between 635 million yuan and 934 million yuan for 2025, primarily due to intensified market competition, liquidity issues, and high financial costs [4]. Group 3: Restructuring Process - A pre-restructuring process was initiated in January 2025 after a creditor filed a notice citing the company's inability to repay debts, although the company is considered to have restructuring value [3]. - The pre-restructuring period has been extended multiple times, with the latest extension pushing the deadline to January 11, 2026, but there remains uncertainty regarding whether the company will formally enter the restructuring process [3].

Core Viewpoint - ST Xiangxue has been facing significant financial challenges, including ongoing lawsuits and a history of losses, leading to a pre-restructuring process initiated due to its inability to meet debt obligations [1][5][7]. Financial Performance - The company's revenue has declined from over 3 billion yuan in 2020 to over 1.8 billion yuan in 2024 [2]. - The net profit attributable to shareholders has been negative for four consecutive years, with losses of -677 million yuan, -530 million yuan, -389 million yuan, and -859 million yuan from 2021 to 2024 [2]. - The cumulative non-recurring net profit from 2017 to 2024 is approximately -2.511 billion yuan, with only one profitable year in 2020 [2]. 2025 Performance Forecast - For 2025, the company expects a net profit loss between 635 million yuan and 934 million yuan, compared to a loss of 859 million yuan in the previous year [2]. - The anticipated non-recurring net profit loss for 2025 is projected to be between 612 million yuan and 899 million yuan [2]. Factors Affecting Performance - The company faces significant financial burdens, including short-term and long-term borrowings amounting to approximately 250 million yuan in financial expenses [3]. - Fixed asset depreciation and amortization are expected to impact around 200 million yuan [3]. - Asset impairment tests are projected to require approximately 130 million yuan for inventory, construction in progress, fixed assets, and development expenditures [3]. - Legal and overdue interest expenses are estimated to be around 220 million yuan [4]. - Non-recurring gains and losses are expected to influence net profit by about 30 million yuan [5]. Pre-restructuring Process - In January 2025, the company received a notice from creditor Guangdong Jinglong Construction Group, leading to a pre-restructuring application due to its inability to repay debts [5]. - The pre-restructuring period was initially set for three months but has been extended multiple times, with the latest extension to January 11, 2026 [5]. Regulatory Issues - The company has faced administrative penalties for information disclosure violations, resulting in a fine of 6 million yuan and warnings to its actual controller [7]. - The stock was suspended for one day due to these violations and has been placed under risk warnings, changing its name to ST Xiangxue [7]. Market Performance - As of February 6, ST Xiangxue's stock price was 9.50 yuan per share, with a total market capitalization of 6.282 billion yuan [8].

证券代码:300147 证券简称: ST 香雪 公告编号:2026—002 广州市香雪制药股份有限公司 关于累计诉讼事项的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州市香雪制药股份有限公司（以下简称"公司"）对公司及子公司连续十 二个月累计涉及诉讼事项进行了统计，现将有关情况公告如下： 一、累计诉讼事项的基本情况 根据《深圳证券交易所股票上市规则（2025 年修订）》的有关规定，上市公 司连续十二个月内发生的诉讼、仲裁事项，涉案金额超过 1,000 万元，且占上市 公司最近一期经审计净资产绝对值 10%以上的，应当及时披露，已经履行披露义 务的，不再纳入累计计算范围。截至本公告披露日，除已经披露的诉讼事项外， 公司及子公司连续十二个月内作为被告累计涉及的诉讼事项涉案金额合计约 9,226.56 万元，占最近一期经审计净资产 8.78%。具体如下： | 原告 | 被告 | 案由 | 进展 | 金额/万元 | | --- | --- | --- | --- | --- | | 广西玉林博康药业有限公司 | 广东化州中药厂制药有限公司、公司 | 合同纠 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.98% on February 2, with Jilin Aodong leading the drop [1] - The Shanghai Composite Index closed at 4015.75, down 2.48%, while the Shenzhen Component Index closed at 13824.35, down 2.69% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Weikang Pharmaceutical (300878) with a closing price of 27.93, up 6.68% [1] - Foci Pharmaceutical (002644) with a closing price of 9.21, up 4.66% [1] - Significant decliners included: - Jilin Aodong (000623) with a closing price of 18.88, down 7.63% [2] - Datang Pharmaceutical (920433) with a closing price of 5.86, down 3.46% [2] Trading Volume and Capital Flow - The Chinese medicine sector saw a net outflow of 235 million yuan from institutional investors, while retail investors contributed a net inflow of approximately 51.97 million yuan [2] - The trading volume for Jilin Aodong reached 504,800 shares, with a transaction value of 977 million yuan [2] Individual Stock Capital Flow - Key capital flows for selected stocks included: - Dong'e Ejiao (000423) with a net inflow of 129 million yuan from institutional investors, but a net outflow of 18.04 million yuan from retail investors [3] - Foci Pharmaceutical (002644) had a net inflow of 43.42 million yuan from institutional investors, with a net outflow of 15.68 million yuan from retail investors [3]

Core Viewpoint - ST Xiangxue (300147) is expected to report a net loss of between 635 million yuan and 934 million yuan for the year 2025, indicating significant financial challenges ahead [1] Financial Performance - The projected net loss for 2025 is between 635 million yuan and 934 million yuan [1] - The net loss, excluding non-recurring gains and losses, is anticipated to be between 612 million yuan and 899 million yuan [1]

Financial Projections - The estimated net profit for 2025 is projected to be a loss between CNY 63.519 million and CNY 93.410 million, compared to a loss of CNY 85.856 million in the same period last year[3]. - The estimated net profit after deducting non-recurring gains and losses is projected to be a loss between CNY 61.160 million and CNY 89.942 million, compared to a loss of CNY 81.921 million in the same period last year[3]. Financial Expenses - Financial expenses are expected to be approximately CNY 25 million due to significant short-term and long-term borrowings[5]. - Depreciation and amortization of fixed assets are expected to impact the financials by about CNY 20 million[6]. - An estimated total of CNY 13 million will be required for impairment provisions on inventory, construction in progress, fixed assets, and development expenditures[6]. - Other operating expenses related to litigation and overdue interest are expected to be around CNY 22 million[7]. - The impact of non-recurring gains and losses on net profit is estimated to be about CNY 3 million[8]. Operational Status - The overall operating condition of the company is reported to be normal, with ongoing assessments for impairment provisions[9]. - The final impairment provision amounts will be determined after evaluation and audit by appointed assessment and audit agencies[9]. - The company aims to enhance profitability and achieve sustainable and stable operations[9].

Group 1 - The Chinese medicine sector saw a rise of 0.54% on January 20, with *ST Changyao leading the gains [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] - Notable gainers in the Chinese medicine sector included *ST Changyao with a closing price of 0.53, up 20.45%, and ST Xiangxue with a closing price of 9.72, up 7.05% [1] Group 2 - The Chinese medicine sector experienced a net outflow of 23.25 million yuan from major funds, while retail investors saw a net inflow of 20.95 million yuan [2] - The top stocks by net inflow from retail investors included *ST Changyao and ST Xiangxue, with retail inflows of 2.20 million yuan and 4.16 million yuan respectively [3] - Major funds showed a significant net outflow in stocks like Zhongsheng Pharmaceutical and Yiling Pharmaceutical, with net outflows of 10.68 million yuan and 5.57 million yuan respectively [3]

Market Overview - The Shanghai Composite Index is at 4164.11 points, slightly above the five-day moving average, with a change of -0.03% [1] - The total trading volume of A-shares is 18505.22 billion yuan, with 228 A-shares breaking through the five-day moving average [1] Stocks with Significant Deviation - The stocks with the largest deviation from the five-day moving average include: - Dapeng Industrial (证券代: 920091) with a deviation of 8.06% and a price increase of 10.14% [1] - Hongxing Development (证券代: 600367) with a deviation of 7.42% and a price increase of 10.01% [1] - Prologis Pharmaceutical (证券代: 000739) with a deviation of 7.37% and a price increase of 10.03% [1] Additional Notable Stocks - Other notable stocks with significant price movements include: - Lek Electric (证券代: 603355) with a deviation of 7.20% and a price increase of 9.99% [1] - Tianyi Medical (证券代: 301097) with a deviation of 6.87% and a price increase of 11.59% [1] - Meihu Co., Ltd. (证券代: 603319) with a deviation of 6.30% and a price increase of 7.73% [1] Stocks with Smaller Deviations - Stocks that have just crossed the five-day moving average with smaller deviations include: - Cangge Mining (证券代: 300300) with a deviation of 3.83% and a price increase of 5.01% [1] - ST Xiangxue (证券代: 300147) with a deviation of 3.57% and a price increase of 4.79% [1] - Shandong Molong (证券代: 002490) with a deviation of 3.43% and a price increase of 5.62% [1]